Evidence map›Paper›PMID 42820111›Full record

ReviewNeuro-oncology advances

Targeting the Siglec/sialic-acid axis in glioblastoma: Glycome-mediated immune evasion and emerging therapeutic platforms.

David Lee, William ElNemer, Omar Selim, Parth Patel, Sara Freeman, Hasan Slika, Fnu Ruchika, Henry Brem, Christopher Jackson, Betty M Tyler

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

David LeeDepartment of Neurosurgery, Johns Hopkins University, School of Medicine, Baltimore, Maryland.
William ElNemerDepartment of Neurosurgery, Johns Hopkins University, School of Medicine, Baltimore, Maryland.
Omar SelimDepartment of Neurosurgery, Johns Hopkins University, School of Medicine, Baltimore, Maryland.
Parth PatelDepartment of Neurosurgery, Johns Hopkins University, School of Medicine, Baltimore, Maryland.
Sara FreemanDepartment of Neurosurgery, Johns Hopkins University, School of Medicine, Baltimore, Maryland.
Hasan SlikaDepartment of Neurosurgery, Johns Hopkins University, School of Medicine, Baltimore, Maryland.
Fnu RuchikaDepartment of Neurosurgery, Johns Hopkins University, School of Medicine, Baltimore, Maryland.
Henry BremDepartment of Neurosurgery, Johns Hopkins University, School of Medicine, Baltimore, Maryland.
Christopher JacksonDepartment of Neurosurgery, Johns Hopkins University, School of Medicine, Baltimore, Maryland.
Betty M TylerDepartment of Neurosurgery, Johns Hopkins University, School of Medicine, Baltimore, Maryland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite encouraging advances in cancer immunotherapy, several malignancies leverage resistance pathways to escape the effects of treatment. Abnormal cell signaling and cytokine secretion modulated by cancer cells promote a tumor microenvironment (TME), wherein the efficacy of infiltrating immune cells is diminished. There is increasing evidence that alteration of the glycosylation profile of some TMEs is a key factor in exhausting the immune response. The sialic-acid/Siglec axis has received attention for its suspected involvement in this context through both preclinical study and several clinical trials. Against this backdrop, glioblastoma (GBM) is a well-established immune-suppressive tumor with disappointing responses to most traditional immunotherapies. Recent studies have suggested that GBM can exploit the sialic-acid/Siglec axis to promote immune evasion and resistance to traditional immune checkpoint inhibitors. This review examines all presently identified Siglec interactions and the current state of Siglec-centered therapies with respect to GBM.

Indexed as

glioblastomaimmune-checkpoint blockadeimmunotherapysialic acidSiglec

Identifiers

PMID42820111
PMCPMC13626132

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.